Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Clin Exp Immunol ; 176(2): 291-300, 2014 May.
Artigo em Inglês | MEDLINE | ID: mdl-24460857

RESUMO

Immune thrombocytopenic purpura (ITP) is acquired autoimmune disease in children characterized by the breakdown of immune tolerance. This work is designed to explore the contribution of different lymphocyte subsets in acute and chronic ITP children. Imbalance in the T helper type 1 (Th1)/Th2 cytokine secretion profile was investigated. The frequency of T (CD3(+), CD4(+), CD8(+)) and B (CD19(+)) lymphocytes, natural killer (NK) (CD16(+) 56(+)) and regulatory T (T(reg)) [CD4(+) CD25(+high) forkhead box protein 3 (FoxP3)(+) ] cells was investigated by flow cytometry in 35 ITP children (15 acute and 20 chronic) and 10 healthy controls. Plasma levels of Th1 cytokines [interferon (IFN-γ) and tumour necrosis factor (TNF-α)] and Th2 [interleukin (IL)-4, IL-6 and IL-10)] cytokines were measured using enzyme-linked immunosorbent assay (ELISA). The percentage of Treg (P < 0·001) and natural killer (NK) (P < 0·001) cells were significantly decreased in ITP patients compared to healthy controls. A negative correlation was reported between the percentage of T(reg) cells and development of acute (r = -0·737; P < 0·01) and chronic (r = -0·515; P < 0·01) disease. All evaluated cytokines (IFN-γ, TNF-α, IL-4, IL-6 and IL-10) were elevated significantly in ITP patients (P < 0·001, P < 0·05, P < 0·05, P < 0·05 and P < 0·001, respectively) compared to controls. In conclusion, our data shed some light on the fundamental role of immune cells and their related cytokines in ITP patients. The loss of tolerance in ITP may contribute to the dysfunction of T(regs). Understanding the role of T cell subsets will permit a better control of autoimmunity through manipulation of their cytokine network.


Assuntos
Subpopulações de Linfócitos B/imunologia , Citocinas/imunologia , Púrpura Trombocitopênica Idiopática/imunologia , Subpopulações de Linfócitos T/imunologia , Subpopulações de Linfócitos B/metabolismo , Criança , Pré-Escolar , Citocinas/sangue , Citocinas/metabolismo , Ensaio de Imunoadsorção Enzimática , Feminino , Citometria de Fluxo , Humanos , Lactente , Interferon gama/sangue , Interferon gama/imunologia , Interferon gama/metabolismo , Interleucina-10/sangue , Interleucina-10/imunologia , Interleucina-10/metabolismo , Interleucina-4/sangue , Interleucina-4/imunologia , Interleucina-4/metabolismo , Interleucina-6/sangue , Interleucina-6/imunologia , Interleucina-6/metabolismo , Masculino , Púrpura Trombocitopênica Idiopática/sangue , Subpopulações de Linfócitos T/metabolismo , Células Th1/imunologia , Células Th1/metabolismo , Células Th2/imunologia , Células Th2/metabolismo , Fator de Necrose Tumoral alfa/sangue , Fator de Necrose Tumoral alfa/imunologia , Fator de Necrose Tumoral alfa/metabolismo
2.
IEEE Trans Vis Comput Graph ; 18(12): 2392-401, 2012 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-26357147

RESUMO

This paper introduces a new feature analysis and visualization method for multifield datasets. Our approach applies a surface-centric model to characterize salient features and form an effective, schematic representation of the data. We propose a simple, geometrically motivated, multifield feature definition. This definition relies on an iterative algorithm that applies existing theory of skeleton derivation to fuse the structures from the constitutive fields into a coherent data description, while addressing noise and spurious details. This paper also presents a new method for non-rigid surface registration between the surfaces of consecutive time steps. This matching is used in conjunction with clustering to discover the interaction patterns between the different fields and their evolution over time. We document the unified visual analysis achieved by our method in the context of several multifield problems from large-scale time-varying simulations.

3.
East Mediterr Health J ; 15(1): 85-93, 2009.
Artigo em Inglês | MEDLINE | ID: mdl-19469430

RESUMO

This cross-sectional study evaluated the immune status of non-vaccinated healthy infants to determine if it is possible to replace both measles vaccine (at 9 months) and measles, mumps and rubella (MMR) vaccine (at 18 months) with a single dose of MMR at 12 months. Serum samples from 566 children in Alexandria, Egypt showed a significant decrease in the seropositive rate to the 3 viral diseases with increasing age, but a significant increase in the seropositive rate among infants who were ranked 1st or 2nd in their family, full-term or born to mothers with no history of hypertension during pregnancy. We recommend administration of the first dose of MMR vaccine between 9 and 12 months of age, and a booster dose of MMR vaccine at 4 years of age.


Assuntos
Vacina contra Sarampo , Vacina contra Sarampo-Caxumba-Rubéola , Avaliação das Necessidades/organização & administração , Vacinação/métodos , Fatores Etários , Análise de Variância , Pré-Escolar , Estudos Transversais , Egito/epidemiologia , Feminino , Diretrizes para o Planejamento em Saúde , Humanos , Esquemas de Imunização , Imunização Secundária/métodos , Lactente , Recém-Nascido , Masculino , Sarampo/epidemiologia , Sarampo/imunologia , Sarampo/prevenção & controle , Vacina contra Sarampo/administração & dosagem , Vacina contra Sarampo/imunologia , Vacina contra Sarampo-Caxumba-Rubéola/administração & dosagem , Vacina contra Sarampo-Caxumba-Rubéola/imunologia , Caxumba/epidemiologia , Caxumba/imunologia , Caxumba/prevenção & controle , Rubéola (Sarampo Alemão)/epidemiologia , Rubéola (Sarampo Alemão)/imunologia , Rubéola (Sarampo Alemão)/prevenção & controle , Estudos Soroepidemiológicos
4.
(East. Mediterr. health j).
em Inglês | WHO IRIS | ID: who-117611

RESUMO

This cross-sectional study evaluated the immune status of non-vaccinated healthy infants to determine if it is possible to replace both measles vaccine [at 9 months] and measles, mumps and rubella [MMR] vaccine [at 18 months] with a single dose of MMR at 12 months. Serum samples from 566 children in Alexandria, Egypt showed a significant decrease in the seropositive rate to the 3 viral diseases with increasing age, but a significant increase in the seropositive rate among infants who were ranked 1st or 2nd in their family, full-term or born to mothers with no history of hypertension during pregnancy. We recommend administration of the first dose of MMR vaccine between 9 and 12 months of age, and a booster dose of MMR vaccine at 4 years of age


Assuntos
Vacina contra Sarampo , Estudos Transversais , Vacina contra Sarampo-Caxumba-Rubéola , Idade Gestacional
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...